Leqembi Trials Aren’t Over; Joining Could Save $26,500 Per Year
Involved in Leqembi? Scientific trials are nonetheless ongoing, and individuals have a 50/50 likelihood of receiving the $26,500-per-year drug free of charge. ...
Cancer Appears to Reduce Dementia Risk – Here’s Why
By Simon Spichak, MSc | January thirty first, 2023 Individuals identified with most cancers are much less more likely to develop...
How to Manage Alzheimer’s Symptoms
By The Being Affected person Editorial Crew | January thirtieth, 2023 From Alzheimer’s medicine, to therapeutic interventions, to house design modifications,...
Being Patient | The Latest Developments on Alzheimer’s Disease
Andrea Couture
Andrea Couture is the writer of “Embracing What Stays,” a memoir about balancing motherhood and daughterhood following her father’s Alzheimer’s prognosis. When my...
Can a Fasting Diet Prevent Alzheimer’s? Q&A With Dr. Valter Longo
By Katy Koop | January twenty sixth, 2023 USC biogerontologist Dr. Valter Longo, founding father of the Prolon fasting-mimicking weight-reduction plan,...
Phil’s Journal: After 17 Marathons, Taking Up the Torch Again for...
By Phil Gutis | January twenty fifth, 2023 Phil Gutis, a reporter and Being Affected person columnist residing with early-onset Alzheimer’s,...
‘Not Your Grandma’s Alzheimer’s’: Ivy League Leader Paves New Path Towards...
By Katy Koop | January twenty fourth, 2023 Following an Alzheimer’s prognosis, school president and writer Rebecca Chopp launched into a...
FDA Declines Rush Request for Alzheimer’s Drug Donanemab
The FDA rejected Eli Lilly’s request to expedite the approval course of for experimental Alzheimer’s drug donanemab, however the drug’s Part 3...
Biotech Leader Wendy Nelson on Living With ApoE4, the Alzheimer’s Gene
By Katy Koop | January twentieth, 2023 With a 23andMe take a look at, Wendy Nelson, Ph.D., found she carries two...
Phil’s Journal: Better Cognitive Assessments Are On the Way—I Tried One
By Phil Gutis | January nineteenth, 2023 Profession reporter and Being Affected person columnist Phil Gutis tries a next-generation new cognitive...
- Advertisement -